NCT06626308 Early Biomarkers in Premanifest Huntington's Disease Gene Carriers: a Pilot Study
| NCT ID | NCT06626308 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Grenoble |
| Condition | Huntington Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-02-20 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-02-20 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to investigate if new, early biomarkers of the disease are available in presymptomatic genetic carriers of Huntington\'s diesase compared to healthy subjects. The main questions it aims to answer are: Does functional brain MRI is able to detect early biomarkers of the disease in genetic carriers? Does gait study by a virtual reality device can detect early biomarkers of the disease in genetic carriers? Researchers will compare genetic carriers and healthy subjects to see if new, early biomarkers of the disease can be detected .
Eligibility Criteria
Inclusion Criteria: * 1\. For PMGC: HD diagnosis confirmed by genetic testing (CAG triplets ≥36 in HTT gene); Unified Huntington Disease Rating Scale19 Total Motor Score (UHDRS-TMS) ≤ 5; age 18-70 years old. 2. For HC: normal neurological examination; age 18-70 years old. Exclusion Criteria: * Main exclusion criteria for both PMGC and HS will be: major ophthalmologic and psychiatric active diseases; cognitive impairment (Montreal Cognitive Assessment, MoCA score \< 25/30); gait issues related to non-neurological conditions; contraindications to brain MRI.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06626308 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Huntington Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06626308 currently recruiting?
Yes, NCT06626308 is actively recruiting participants. Contact the research team at smeoni@chu-grenoble.fr for enrollment information.
Where is the NCT06626308 trial being conducted?
This trial is being conducted at Grenoble, France.
Who is sponsoring the NCT06626308 clinical trial?
NCT06626308 is sponsored by University Hospital, Grenoble. The trial plans to enroll 20 participants.